INTRODUCTION
NAFLD, NASH, noncirrhotic NASH, TNF-α
CHRONIC LIVER DISEASE
NASH is a progressive form of NAFLD, one of the most common chronic liver diseases worldwide.Therapies targeting different pathogenic pathways in NASH are under investigation including nuclear receptor agonists like farnesoid X receptor (FXR), antioxidants, anti-inflammatory agents, antifibrotic agents, and modulators of the TNF-α pathway, among others.There are no approved therapies globally for NASH, with many of the investigational agents studied to date either failing to meet histological end points or demonstrating limited efficacy.Tropifexor (TXR), a potent nonbile acid FXR agonist, has been shown to be highly efficacious in animal modelsCenicriviroc (CVC), a potent inhibitor of C-C chemokine receptor types 2/5 (CCR2/5), has demonstrated antifibrotic and anti-inflammatory properties in animal models.The purpose of this study was to assess the safety and efficacy of the TXR and CVC combination in patients with noncirrhotic NASH compared with respective monotherapies.